Results 1 to 10 of about 41,661 (291)
Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy. [PDF]
PLoS ONE, 2018 PURPOSE:Intermittent androgen deprivation therapy is an effective treatment for metastatic prostate cancer. However, no study to date has evaluated the long-term outcomes of this treatment among patients with prostate cancer after radical prostatectomy ...
Shintaro Maru +5 more
doaj +2 more sources
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis [PDF]
Frontiers in Endocrinology, 2023 ObjectivesAndrogen deprivation therapy combined with radiotherapy for intermediate-risk prostate cancer is still a matter of debate. We conducted a meta-analysis to evaluate the necessity of androgen deprivation therapy combined with radiotherapy for ...
Jiuzhou Chen +14 more
doaj +2 more sources
Epidemiological profile of COVID-19 in patients with prostate cancer undergoing androgen deprivation therapy at a Brazilian Cancer Center [PDF]
Einstein (São Paulo), 2023 Objective To describe the epidemiological aspects of COVID-19 in patients with prostate cancer who received androgen deprivation therapy and those who did not.
Isabela Granato Travalini +6 more
doaj +1 more source
Indications and Complications of Androgen Deprivation Therapy [PDF]
Seminars in Oncology Nursing, 2020 To review the indications for and side effects of androgen deprivation therapy (ADT) in men affected by prostate cancer.National guidelines, evidence-based summaries, peer-reviewed studies, and websites.Indications for ADT include men with (1) intermediate- to high-risk localised prostate cancer undergoing radiation therapy, (2) biochemical recurrence ...
Fankhauser, Christian Daniel +5 more
openaire +3 more sources
Cardiovascular Toxicity of Androgen Deprivation Therapy [PDF]
Current Cardiology Reports, 2021 Androgen deprivation therapy (ADT) is the standard of care for the treatment of advanced prostate cancer (PC). ADT, particularly with GnRH agonists, leads to increased risk of cardiovascular disease, including myocardial infarction, hypertension, and stroke.
Julia Boland +3 more
openaire +2 more sources
Impact of advanced prostatic cancer treatment on quality of life and sexual function
Brazilian Journal of Oncology, 2023 INTRODUCTION: The studying the quality of life after cancer treatment has become a priority in oncology. Objectives: To evaluate the impact of different treatments for recurrence prostate cancer on quality of life and sexual activity.
Fernando Parma Marsicano, Andy Petroianu
doaj +1 more source
Androgen Deprivation Therapy and Cardiovascular Risk [PDF]
Nephro-Urology Monthly, 2012 Androgen deprivation therapy (ADT) is an established therapy for metastatic prostate cancer (PC) and some cases of locally advanced and/or localized PC (1). However, concerns have been raised about the cardiovascular side effects of ADT and their impact on the survival of elderly patients with PC (1).
Mourmouris, P. +2 more
openaire +3 more sources
Androgen deprivation therapy and hormonal status in men with COVID-19
Вестник урологии, 2023 Severe course of COVID-19 among men compared to the female led to a detailed study of the hormonal status of men with COVID-19. The earliest works about this focused on the incidence and severity of COVID-19 depending on the intake of androgen ...
A. A. Kamalov +4 more
doaj +1 more source
Cardiovascular Toxicities of Androgen Deprivation Therapy [PDF]
Current Treatment Options in Oncology, 2021 Prostate cancer is the second leading cause of cancer death in men, and cardiovascular disease is the number one cause of death in patients with prostate cancer. Androgen deprivation therapy, the cornerstone of prostate cancer treatment, has been associated with adverse cardiovascular events.
Azariyas A. Challa +12 more
openaire +2 more sources
IJU Case Reports, 2022 Introduction Recent studies have indicated an improvement in the survival rate of patients using docetaxel in addition to androgen deprivation therapy for high‐volume metastatic hormone‐sensitive prostate cancer.
Kenichi Hata +3 more
doaj +1 more source